Grundläggande statistik
| CIK | 1310094 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| August 15, 2013 |
- FOR PERIOD ENDED JUNE 30, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-51383 CUSIP NUMBER 00430L103 (Check One) o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2013 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transiti |
|
| July 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2013 ACCENTIA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida (State or Other Jurisdiction of Incorporation) 000-51383 (Commission Fil |
|
| May 15, 2013 |
- FOR PERIOD ENDED MARCH 31, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 15, 2015 Estimated average burden hours per response . . . . . 2.50 SEC FILE NUMBER 000-51383 CUSIP NUMBER 00430L103 (Check One) oForm 10-K oForm 20-F oForm 11-K xForm 10-Q oForm 10-D oForm N-SAR oForm N-CSR For Period Ended: March 31, 2 |
|
| March 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2013 ACCENTIA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Florida (State or Other Jurisdiction of Incorporation) 000-51383 (Commission File Nu |
|
| February 22, 2013 |
Accentia Biopharmaceuticals, Inc. 324 South Hyde Park Avenue, Suite 350 Tampa, FL 33606 February 22, 2013 VIA EDGAR AND OVERNIGHT COURIER Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Division of Corporation Finance Re: Accentia Biopharmaceuticals, Inc. Withdrawal of Registration Statem |
|
| February 22, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2013 ACCENTIA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Florida (State or Other Jurisdiction of Incorporation) 000-51383 (Commission Fil |
|
| February 14, 2013 |
Quarterly Report - FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-51383 ACCENTIA BIOPHAR |
|
| December 26, 2012 |
Amended and Restated Common Stock Purchase Warrant Exhibit 10.69 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OF |
|
| December 26, 2012 |
Common Stock Purchase Warrant Exhibit 10.70 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT |
|
| December 26, 2012 |
AMENDED & RESTATED SECURITY AGREEMENT Amended and Restated Security Agreement Exhibit 10.68 AMENDED & RESTATED SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”) is made and is entered into as of the 13th day of June, 2011, by ACCENTIA BIOPHARMACEUTICALS, INC., a Florida corporation (the “Borrower”), in favor of CORPS REAL, LLC, an Illinois limited liability company (the “Secured Party”). Recitals WHEREAS, pursuant to that |
|
| December 26, 2012 |
Security Agreement Exhibit 10.74 SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”) is made and is entered into as of the 20th day of December, 2012, by ACCENTIA BIOPHARMACEUTICALS, INC., a Florida corporation (the “Borrower”), in favor of PABETI, INC., an Illinois limited liability company (the “Secured Party”). Recitals WHEREAS, pursuant to that certain Secured Promissory Note of even |
|
| December 26, 2012 |
AMENDED & RESTATED SECURITY AGREEMENT Amended and Restated Security Agreement Exhibit 10.71 AMENDED & RESTATED SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”) is made and is entered into as of the 1st day of June, 2012, by ACCENTIA BIOPHARMACEUTICALS, INC., a Florida corporation (the “Borrower”), in favor of PABETI, INC., an Illinois limited liability company (the “Secured Party”). Recitals WHEREAS, pursuant to that cert |
|
| December 26, 2012 |
Standstill Agreement Exhibit 10.72 STANDSTILL AGREEMENT THIS STANDSTILL AGREEMENT (the “Agreement”) is made and entered into effective as of November 17, 2012, by and among (i) BIOVEST INTERNATIONAL, INC., a Delaware corporation (“Biovest”); (ii) CORPS REAL, LLC, an Illinois limited liability company (the “Senior Lender”); (iii) PSOURCE STRUCTURED DEBT LIMITED, a Guernsey limited liability company |
|
| December 26, 2012 |
SECURED PROMISSORY NOTE $125,000 December 20, 2012 Tampa, Florida Secured Promissory Note Exhibit 10.73 SECURED PROMISSORY NOTE $125,000 December 20, 2012 Tampa, Florida FOR VALUE RECEIVED, the undersigned, ACCENTIA BIOPHARMACEUTICALS, INC., a Florida corporation (the “Borrower”), with a mailing address of 324 South Hyde Park Avenue, Suite 350, Tampa, Florida 33606, hereby promises to pay to the order of Pabeti, Inc., an Illinois limited liability company (the “ |
|
| December 26, 2012 |
Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 23, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2012 ACCENTIA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 000-51383 04-3639490 (State or Other Jurisdiction of Incorp |
|
| October 15, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2012 ACCENTIA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 000-51383 04-3639490 (State or Other Jurisdiction of Incorpor |
|
| August 14, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2012 ACCENTIA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 000-51383 04-3639490 (State or Other Jurisdiction of Incorpor |
|
| August 14, 2012 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 14, 2012 |
Press Release Exhibit 99.1 Biovest Conducts End of Phase III Review with FDA of BiovaxID™ as Consolidation Therapy in Non-Hodgkin’s Lymphoma Company identifies potential biomarker associated with significant increase in duration of cancer-free survival in vaccinated patients compared to matched controls (P=0.001) TAMPA, FL and MINNEAPOLIS, MN – August 14, 2012 – Biovest International, Inc. (OTCQB: |
|
| August 14, 2012 |
Prospectus Supplement No. 1 Table of Contents Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-182376 PROSPECTUS SUPPLEMENT NO. 1 DATED AUGUST 14, 2012 (To Prospectus Dated and Declared Effective on July 10, 2012) ACCENTIA BIOPHARMACEUTICALS, INC. 1,607,148 Shares Common Stock This Prospectus Supplement No. 1 supplements information contained in, and should be read in co |
|
| August 14, 2012 |
Prospectus Supplement No. 2 Table of Contents Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-180145 PROSPECTUS SUPPLEMENT NO. 2 DATED AUGUST 14, 2012 (To Prospectus Dated and Declared Effective on April 2, 2012) ACCENTIA BIOPHARMACEUTICALS, INC. 1,759,532 Shares Common Stock This Prospectus Supplement No. 2 supplements information contained in, and should be read in co |
|
| June 27, 2012 |
Accentia Biopharmaceuticals, Inc. (“Accentia”) has three direct and indirect subsidiaries: Subsidiaries Exhibit 21 Accentia Biopharmaceuticals, Inc. (“Accentia”) has three direct and indirect subsidiaries: 1. Accentia holds all of the issued and outstanding equity securities of TEAMM Pharmaceuticals, Inc. d/b/a Accentia Pharmaceuticals, a Florida corporation. 2. Accentia holds all of the issued and outstanding equity securities of Accentia Biotech, Inc. f/k/a Analytica International, In |
|
| June 27, 2012 |
Registration Statement - PROSPECTUS Prospectus Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on June 27, 2012 Registration No. |
|
| June 21, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2012 ACCENTIA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 000-51383 04-3639490 (State or Other Jurisdiction of Incorporat |
|
| June 21, 2012 |
Form of Common Stock Purchase Warrant Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD |
|
| June 21, 2012 |
Form of Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT is made and effective as of June , 2012 (the “Effective Date”) by and between Accentia Biopharmaceuticals, Inc., a Florida corporation with a place of business located at 324 South Hyde Park Avenue, Suite 350, Tampa, FL 33606 (the “Company” or “Accentia”), and , with an address of (“Subscriber”), as foll |
|
| June 7, 2012 |
Common Stock Purchase Warrant Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT P |
|
| June 7, 2012 |
AMENDMENT No. 1 To Plan Convertible Promissory Note Amendment to Convertible Promissory Note Exhibit 10.4 AMENDMENT No. 1 To Plan Convertible Promissory Note This Amendment No. 1 to Plan Convertible Promissory Note dated November 17, 2010 (hereinafter, the “Note”) effective as of June 6, 2012 (“Effective Date”) by and between Accentia Biopharmaceuticals, Inc., a Florida corporation having an address at 324 South Hyde Park Avenue, Suite 350, Tampa, |
|
| June 7, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2012 ACCENTIA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 000-51383 04-3639490 (State or Other Jurisdiction of Incorporati |
|
| June 7, 2012 |
Security Agreement Exhibit 10.3 SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”) is made and is entered into as of the 1st day of June, 2012, by ACCENTIA BIOPHARMACEUTICALS, INC., a Florida corporation (the “Borrower”), in favor of PABETI, INC., an Illinois limited liability company (the “Secured Party”). Recitals WHEREAS, pursuant to that certain Secured Promissory Note of even date |
|
| June 7, 2012 |
SECURED PROMISSORY NOTE $1,500,000.00 June 1, 2012 Tampa, Florida Secured Promissory Note Exhibit 10.1 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATE |
|
| May 15, 2012 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 15, 2012 |
Prospectus Supplement Table of Contents Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. |
|
| May 15, 2012 |
Letter Agreement Exhibit 10.1 LV ADMINISTRATIVE SERVICES, INC. as Administrative and Collateral Agent 420 LEXINGTON AVENUE, SUITE 2840 NEW YORK, NY 10170 MAY 10, 2012 Biovest International, Inc. 324 South Hyde Park Avenue, Suite 350 Tampa, Florida 33606 Attn: Chief Executive Officer/President Re: Sale and/or Repayment of Biovest Term Notes Ladies and Gentlemen: Reference is made to: (a) that certa |
|
| April 13, 2012 |
Amendment No 1 to Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 15, 2012 |
Accentia Biopharmaceuticals, Inc. (“Accentia”) has three direct and indirect subsidiaries: Subsidiaries of the Registrant Exhibit 21 Accentia Biopharmaceuticals, Inc. (“Accentia”) has three direct and indirect subsidiaries: 1. Accentia holds all of the issued and outstanding equity securities of TEAMM Pharmaceuticals, Inc. d/b/a Accentia Pharmaceuticals, a Florida corporation. 2. Accentia holds all of the issued and outstanding equity securities of Accentia Biotech, Inc. f/k/a Analytica |
|
| March 15, 2012 |
Amendment No. 2 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on March 15, 2012 Registration No. 333-172353 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ACCENTIA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Florida 28 |
|
| March 15, 2012 |
Registration Statement - FORM S-1 FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on March 15, 2012 Registration No. |
|
| March 15, 2012 |
Accentia Biopharmaceuticals, Inc. (“Accentia”) has three direct and indirect subsidiaries: Subsidiaries Exhibit 21 Accentia Biopharmaceuticals, Inc. (“Accentia”) has three direct and indirect subsidiaries: 1. Accentia holds all of the issued and outstanding equity securities of TEAMM Pharmaceuticals, Inc. d/b/a Accentia Pharmaceuticals, a Florida corporation. 2. Accentia holds all of the issued and outstanding equity securities of Accentia Biotech, Inc. f/k/a Analytica International, In |
|
| March 14, 2012 |
March 14, 2012 Via E-mail Garrison J. Hasara, CPA Acting Chief Financial Officer; Controller (Principal Financial Officer and Principal Accounting Officer) Accentia Biopharmaceuticals, Inc. 324 South Hyde Park Ave., Suite 350 Tampa, FL 33606 Re: Accentia Biopharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended September 30, 2011 Filed December 19, 2011 File No. 000-51383 Dear Mr. Hasara: We ha |
|
| March 12, 2012 |
Correspondence March 12, 2012 Mr. Jim Rosenberg Senior Assistant Chief Accountant Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Accentia Biopharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended September 30, 2011 Filed December 19, 2011 Form 10-Q for the Quarterly Period Ended December 31, 2011 Filed February 10, 2012 File No. 000-51383 Dear Mr. Rosenberg: On |
|
| March 8, 2012 |
Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2012 ACCENTIA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Florida 000-51383 04-3639490 (State or Other Jurisdiction of Incorporation) |
|
| March 7, 2012 |
March 7, 2012 Via E-mail Garrison J. Hasara, CPA Acting Chief Financial Officer; Controller (Principal Financial Officer and Principal Accounting Officer) Accentia Biopharmaceuticals, Inc. 324 South Hyde Park Ave., Suite 350 Tampa, FL 33606 Re: Accentia Biopharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended September 30, 2011 Filed December 19, 2011 Form 10-Q for the Quarterly Period Ended D |
|
| March 6, 2012 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2012 ACCENTIA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 000-51383 04-3639490 (State or Other Jurisdiction of Incorp |
|
| February 10, 2012 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 6, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*./@94P`C$+`P<#7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3)= M+TUE9&EA0F]X6S`@," |
|
| February 3, 2012 |
Accentia Biopharmaceuticals, Inc. (“Accentia”) has three direct and indirect subsidiaries: Subsidiaries of the Registrant Exhibit 21 Accentia Biopharmaceuticals, Inc. (“Accentia”) has three direct and indirect subsidiaries: 1. Accentia holds all of the issued and outstanding equity securities of TEAMM Pharmaceuticals, Inc. d/b/a Accentia Pharmaceuticals, a Florida corporation. 2. Accentia holds all of the issued and outstanding equity securities of Accentia Biotech, Inc. f/k/a Analytica |
|
| February 3, 2012 |
Amendment # 1 Table of Contents As filed with the Securities and Exchange Commission on February 3, 2012 Registration No. |
|
| February 2, 2012 |
Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT is made and effective as of January 27, 2012 (the “Effective Date”) by and between Accentia Biopharmaceuticals, Inc., a Florida corporation with a place of business located at 324 South Hyde Park Avenue, Suite 350, Tampa, FL 33606 (the “Company” or “Accentia”), and REF HOLDINGS, LLC, with an address of 801 North |
|
| February 2, 2012 |
Common Stock Purchase Warrant Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT P |
|
| February 2, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2012 ACCENTIA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 000-51383 04-3639490 (State or Other Jurisdiction of Incorpo |
|
| February 1, 2012 |
ABPI / / LAURUS MASTER FUND LTD - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (AMENDMENT NO. 4)* ACCENTIA BIOPHARMACEUTICALS, INC. - (Name of Issuer) Common Stock, par value $0.001 per share - (Title of Class of Securities) 00430L10 - (CUSIP Number) Decemb |
|
| January 20, 2012 |
Definitive Proxy Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 20, 2012 |
- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
